Late Breaking Abstract - Interim results from AIR, an open-label, single arm, 36-week ph 2 trial of C21 in subjects with idiopathic pulmonary fibrosis
T. Maher (Los angeles, United States), C. Ganslandt (Stockholm, Sweden), R. Batta (Stockholm, Sweden), G. Tornling (Stockholm, Sweden), T. Bengtsson (Stockholm, Sweden), H. Pophale (Mumbai, India), E. Rosendahl (Stockholm, Sweden), T. Maher (Los Angeles, United States)
Source: International Congress 2022 – What is hot in interstitial lung diseases
Session: What is hot in interstitial lung diseases
Session type: Oral Presentation
Number: 1397
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Maher (Los angeles, United States), C. Ganslandt (Stockholm, Sweden), R. Batta (Stockholm, Sweden), G. Tornling (Stockholm, Sweden), T. Bengtsson (Stockholm, Sweden), H. Pophale (Mumbai, India), E. Rosendahl (Stockholm, Sweden), T. Maher (Los Angeles, United States). Late Breaking Abstract - Interim results from AIR, an open-label, single arm, 36-week ph 2 trial of C21 in subjects with idiopathic pulmonary fibrosis. 1397
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|